We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 2 november 2018

The Lancet: [News] Venetoclax with decitabine or azacitidine for AML

[News] Venetoclax with decitabine or azacitidine for AML
Venetoclax, an oral selective inhibitor of the antiapoptotic protein BCL-2, shows encouraging anticancer activity and tolerable safety in older patients with acute myeloid leukaemia (AML) who are unfit for traditional chemotherapy, according to new research.
Read more

[Comment] Interrogating molecular data for medulloblastoma risk stratification
Medulloblastoma is the most common malignant paediatric brain tumour, with an incidence between 2·34 and 5·96 per million population.1 Early studies on medulloblastoma biology were largely inconclusive because of its molecular heterogeneity and the small size of the cohorts analysed. By contrast, more recent studies, based on a large number of internationally collected cases, have produced a deeper understanding of the molecular events that characterise medulloblastoma. Indeed, on the basis of gene expression, genetic aberrations, and DNA methylation, medulloblastoma is now classified into several molecular subgroups.
Read more

[Comment] Evidence-based screening protocols for cervical cancer?
A screening trial is nothing more than a proof of principle. Indeed, there are no comparative effectiveness studies in cervical cancer screening that show what the best interval, stopping age, or management of human papillomavirus (HPV)-positive women is in terms of reduction of cervical cancer incidence and mortality. However, one of the most neglected issues in screening research is the age at which we should stop screening, as noted by Talía Malagón and colleagues in The Lancet Oncology.1 With the introduction of HPV testing in cervical cancer precursor screening, there has been much focus on the age at which to start screening,2,3 but no guideline has dealt with the issue of when to stop testing.
Read more

[News] Carcinogenicity of some nitrobenzenes and other industrial chemicals
In October, 2018, 14 experts from six countries met at the International Agency for Research on Cancer (IARC) in Lyon, France, to finalise their evaluation of the carcinogenicity of ortho-phenylenediamine and its dihydrochloride salt, 2-chloronitrobenzene, 4-chloronitrobenzene, 1,4-dichloro-2-nitrobenzene, 2,4-dichloro-1-nitrobenzene, 2-amino-4-chlorophenol, para-nitroanisole, and N,N-dimethylacetamide. These assessments will be published in Volume 123 of the IARC Monographs.1
Read more

[News] Promising new treatment for multiple myeloma
Selinexor—an oral inhibitor of exportin 1 (XPO1)—might be a safe and tolerable treatment option in combination with low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma, according to recent findings.
Read more